Cargando…

Relationship between FEV(1 )change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review

BACKGROUND: Interactions between spirometry and patient-reported outcomes in COPD are not well understood. This systematic review and study-level analysis investigated the relationship between changes in FEV(1 )and changes in health status with bronchodilator therapy. METHODS: Six databases (to Octo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Westwood, Marie, Bourbeau, Jean, Jones, Paul W, Cerulli, Annamaria, Capkun-Niggli, Gorana, Worthy, Gill
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090353/ https://www.ncbi.nlm.nih.gov/pubmed/21477298 http://dx.doi.org/10.1186/1465-9921-12-40

Ejemplares similares

Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2013)

Responses of FEV(6), FVC, and FET to inhaled bronchodilator in the adult general population
por: Kainu, Annette, et al.
Publicado: (2009)

Bronchodilator Response of FEV6 and FEV3 as Surrogates of Forced Vital Capacity
por: Mehrparvar, Amir Houshang, et al.
Publicado: (2014)

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

Diagnostic accuracy of pre-bronchodilator FEV(1)/FEV(6) from microspirometry to detect airflow obstruction in primary care: a randomised cross-sectional study
por: van den Bemt, Lisette, et al.
Publicado: (2014)

COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV(1) – a post-hoc analysis of pooled data
por: Chai, Chee-Shee, et al.
Publicado: (2023)

Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry
por: Neder, José Alberto, et al.
Publicado: (2019)

A reply to questions raised about FEV(1)Q and bronchodilator responsiveness
por: Miller, Martin R., et al.
Publicado: (2023)

Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension
por: Thom, Howard HZ, et al.
Publicado: (2015)

Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD
por: Cheng, Shih-Lung, et al.
Publicado: (2017)

Bronchodilator response cut-off points and FEV (0.75) reference values for spirometry in preschoolers
por: Burity, Edjane Figueiredo, et al.
Publicado: (2016)

Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials
por: Li, Chenxi, et al.
Publicado: (2019)

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
por: Corrao, Salvatore, et al.
Publicado: (2017)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
por: Kang, Jieun, et al.
Publicado: (2017)

Inflammatory and immunological profiles in patients with COPD: relationship with FEV (1) reversibility
por: Queiroz, Cleriston Farias, et al.
Publicado: (2016)

Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV(1)
por: Agbetile, J, et al.
Publicado: (2012)

"Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD
por: Kostikas, Konstantinos, et al.
Publicado: (2010)

Comparison of the variability of the annual rates of change in FEV(1) determined from serial measurements of the pre- versus post-bronchodilator FEV(1) over 5 years in mild to moderate COPD: Results of the lung health study
por: Tashkin, Donald P, et al.
Publicado: (2012)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Cardiovascular morbidity and the use of inhaled bronchodilators
por: Macie, Christine, et al.
Publicado: (2008)

A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD
por: Jara, Michele, et al.
Publicado: (2012)

Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD
por: Bishwakarma, Raju, et al.
Publicado: (2017)

Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
por: Halpin, David M. G., et al.
Publicado: (2016)

Inhaled corticosteroids, blood eosinophils, and FEV(1) decline in patients with COPD in a large UK primary health care setting
por: Whittaker, Hannah R, et al.
Publicado: (2019)

Three-minute constant rate step test for detecting exertional dyspnea relief after bronchodilation in COPD
por: Borel, Benoit, et al.
Publicado: (2016)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study
por: Kozma, Chris M, et al.
Publicado: (2011)

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid
por: Miravitlles, Marc, et al.
Publicado: (2022)

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety
por: Suissa, Samy, et al.
Publicado: (2022)

Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1)
por: Lange, Peter, et al.
Publicado: (2016)

The role of inhaled and/or nasal corticosteroids on the bronchodilator response
por: Lee, Ju Kyung, et al.
Publicado: (2010)

Inhaled Bronchodilator Use for Infants with Bronchopulmonary Dysplasia
por: Slaughter, Jonathan L, et al.
Publicado: (2014)

Association of blood eosinophils and plasma periostin with FEV(1) response after 3-month inhaled corticosteroid and long-acting beta(2)-agonist treatment in stable COPD patients
por: Park, Hye Yun, et al.
Publicado: (2015)

COPD assessment test and FEV(1): do they predict oxygen uptake in COPD?
por: Carvalho-Jr, Luiz Carlos S, et al.
Publicado: (2018)

Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
por: Calverley, Peter M, et al.
Publicado: (2016)

Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
por: Kardos, Peter, et al.
Publicado: (2016)

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_24lndtr6juo3dosqdvf6npkefh